Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells

David M Davies; John Maher

doi:10.1016/j.ccell.2020.12.019

Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells

Cancer Cell. 2021 Feb 8;39(2):138-140. doi: 10.1016/j.ccell.2020.12.019. Epub 2021 Jan 7.

Authors

David M Davies¹, John Maher²

Affiliations

¹ King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.
² King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK; Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK. Electronic address: jmaher@leucid.com.

PMID: 33417830
DOI: 10.1016/j.ccell.2020.12.019

Abstract

CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Hematologic Neoplasms*
Humans
Immunotherapy
Immunotherapy, Adoptive
Neoplasms*
T-Lymphocytes